RxDoctor Payments Data

Robert Joy, MD

Clinical Cardiac Electrophysiology · Schenectady, NYNPI 1073527289

Payments from drug & device makers

$9,846in general payments, 2019–2025

Across 250 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$2K
  • Boston Scientific$428
  • Johnson & Johnson$397
  • Novartis$305
  • Abiomed$279
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$3,86639%
  • Food & beverage$5,98061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,846 in reported general payments places this provider in the 25th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$120,422
Medicare patients
501
Services billed
1,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban665$690,128
XareltoRivaroxaban176$200,764
EntrestoSacubitril/Valsartan68$92,714
JardianceEmpagliflozin25$31,451
FarxigaDapagliflozin Propanediol11$11,576
Metoprolol Succinate533$8,045
Atorvastatin Calcium409$5,404
Ezetimibe60$2,688
Rosuvastatin Calcium110$2,582
Torsemide186$2,569
Eplerenone19$2,005
Potassium Chloride71$1,876
Carvedilol156$1,608
Losartan Potassium155$1,580
Valsartan52$1,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$690,128665 claims
Johnson & JohnsonXarelto$397$200,764176 claims
NovartisEntresto$305$92,71468 claims
Boehringer IngelheimJardiance$232$31,45125 claims
AstraZenecaFarxiga$96$11,57611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →